Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. It's lead product candidate is icovamenib, is designed to be a bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair, it is used for the treatment of menin regulated or dependent diseases such as type 1 and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Market Cap	$98.99M	P/E Ratio	N/A
52W High	$6.44	52W Low	$0.87
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	9.7%
Overall Score	47	Value Score	45
Quality Score	21	Technical Score	75

EPS Current Est	$-1.55	EPS Next Est	$-1.09
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BMEA	$1.41	-7.24%	1.20M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BMEA	$1.41	-7.2%	1.20M
3
4
5
6

BMEA

BMEA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Biomea Fusion Inc. Data in Excel

Get Biomea Fusion Inc. Data in Excel